Arihant Capital's research report on Cipla
Cipla Ltd. is an Indian pharmaceutical major with global presence across America, Europe and Emerging Market regions. It has a strong product portfolio in the respiratory segment. The company has a number of USFDA (United States Food and Drug Administration) compliant plant facilities which supply formulations to the international market.
Outlook
Factoring the future growth opportunities, we value the company at a P/E Multiple of 25x its FY24E EPS of INR 43.2 and arrive at a Target Price of INR 1,080 per share. Accordingly, we recommend a Hold rating on the shares of Cipla Ltd.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
